Nadler Financial Group Inc. Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Nadler Financial Group Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 1.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,932 shares of the biopharmaceutical company’s stock after purchasing an additional 519 shares during the period. Nadler Financial Group Inc.’s holdings in Pfizer were worth $808,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. First Trust Direct Indexing L.P. grew its stake in shares of Pfizer by 45.0% in the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock worth $1,436,000 after buying an additional 16,060 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer in the 1st quarter worth about $315,000. Norden Group LLC boosted its stake in Pfizer by 26.8% in the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock worth $842,000 after purchasing an additional 6,404 shares in the last quarter. Private Advisor Group LLC increased its stake in Pfizer by 12.8% during the 1st quarter. Private Advisor Group LLC now owns 652,208 shares of the biopharmaceutical company’s stock valued at $18,099,000 after purchasing an additional 74,168 shares in the last quarter. Finally, Mission Wealth Management LP lifted its stake in shares of Pfizer by 2.8% in the first quarter. Mission Wealth Management LP now owns 73,894 shares of the biopharmaceutical company’s stock worth $2,051,000 after buying an additional 2,004 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PFE shares. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

Shares of PFE traded up $0.18 during midday trading on Friday, hitting $28.48. 3,566,246 shares of the company traded hands, compared to its average volume of 37,059,504. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a 50 day moving average of $29.05 and a 200-day moving average of $28.56. The stock has a market cap of $161.39 billion, a price-to-earnings ratio of 38.23, a PEG ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) EPS. The company’s revenue was up 31.2% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.90%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.